Edgewise Sells Muscular Dystrophy Program for $2.65B to Fund Heart Pipeline

In a strategic move reflecting the biotech sector's shift toward high-conviction assets, Edgewise Therapeutics has sold its muscular dystrophy program to Servier in a deal valued at $2.65 billion. The company is set to receive $1.55 billion in upfront cash, which will be utilized to fully fund the development of its lead candidate, EDG-7500, for hypertrophic cardiomyopathy. According to the agreement, Phase 2 data for this heart program is anticipated in the second quarter of 2026 before advancing to pivotal Phase 3 trials.

This transaction aligns with a broader trend of consolidation in the biotechnology industry, where major players are acquiring specialized pipelines; for instance, Vertex Pharmaceuticals recently acquired Alpine Immune Sciences for $4.9 billion per market reports. The massive cash injection de-risks Edgewise's balance sheet, allowing it to bypass dilutive equity raises while maintaining a competitive edge over peers who may face tighter financing conditions in the current high-rate environment.

Traders should monitor Edgewise (EWTX) stock as it approaches key clinical milestones, with the Q2 2026 data release serving as the primary catalyst. Furthermore, upcoming macroeconomic indicators, including U.S. inflation data and Fed speeches, will likely influence risk sentiment across the biotech sector, potentially impacting the valuation of growth-oriented companies as they navigate the path toward commercialization.